Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Fiche publication

Date publication

décembre 2026

Journal

Journal of medical economics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis

Tous les auteurs :
Dimopoulos MA, Boccadoro M, Einsele H, Rodriguez-Otero P, Hulin C, Perrot A, Leleu X, Caillot D, Facon T, Mina R, Gay F, Broijl A, Hajek R, Spencer A, Schjesvold F, Zweegman S, Nair S, Ammann E, He J, Nobrega M, Rowe M, Sitthi-Amorn A, Sonneveld P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41701105

Résumé

To compare the effectiveness of induction and consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) plus maintenance therapy with daratumumab and lenalidomide (DR) with 2 treatment regimens that are widely used for transplant-eligible newly diagnosed multiple myeloma (TE NDMM): bortezomib, thalidomide, and dexamethasone (VTd) or daratumumab-VTd (DVTd) followed by observation (Obs) or lenalidomide maintenance.